Benign Prostatic Hyperplasia (BPH) Treatment Market: By Treatment Type (BPH Drugs, BPH Devices), By Distribution Channel (Institutional Sales, Retail Sales, Online Pharmacies), By Geography (North America, Europe, Asia, Pacific, Latin America, and MEA) and forecast to 2030.

Benign Prostatic Hyperplasia (BPH) Treatment Market size was valued at USD 11.6 million in 2023 and is expected to grow at a CAGR of 5.6% from 2024 to 2030. BPH, a non-cancerous enlargement of the prostate gland, affects a significant portion of the male population over 50, leading to various urinary symptoms and impacting quality of life. The increasing prevalence of BPH, coupled with the aging global population, drives market growth. Additionally, advancements in drug therapies and minimally invasive devices contribute to market expansion by offering more effective and patient-friendly treatment options. In the BPH Drugs segment, combination therapies combining alpha-blockers with 5-alpha reductase inhibitors have gained traction due to their comprehensive approach to symptom relief. The introduction of novel drug classes like PDE-5 inhibitors for BPH treatment has further expanded the pharmaceutical options available to patients.

In the BPH Devices segment, innovations in minimally invasive technologies such as transurethral RF thermal therapy devices and suture-based implant systems have revolutionized treatment approaches, offering alternatives to traditional surgical interventions. The market is also benefiting from increased awareness about prostate health and improved healthcare access in developing countries. However, challenges such as side effects of certain medications, the high cost of advanced devices, and potential complications from long-term use of some treatments may hinder market growth. The North America region held the major market share in 2023 and is expected to dominate the global BPH Treatment Market in the forecasted years, driven by advanced healthcare infrastructure and high awareness levels.

Benign Prostatic Hyperplasia (BPH) Treatment Market Key Developments:

In May 2022, Teleflex Incorporated announced the launch of the UroLift Advanced Tissue Control (ATC) System. This new system:

• Enhances the UroLift  System for treating benign prostatic hyperplasia (BPH)
• Features an adjustable EverClear  Obturator to improve visualization
• Provides real-time tissue control during the procedure

In December 2021, Olympus Corporation announced FDA 510(k) clearance for the iTind procedure for treating BPH. This development:

• Expands Olympus' BPH treatment portfolio
• Offers a minimally invasive option that can be performed in-office or as an outpatient procedure
• Provides a treatment that does not require implants or cause sexual dysfunction